DRMA heads into its May 14 earnings print with insiders deeply committed — and short sellers cooling off from a frenzied spring.
The clearest signal in the data is insider conviction. The CEO, CFO, and a founder each bought stock in December 2025 at $2.04 per share. CEO Gerald Proehl committed roughly $1.25 million across two purchases alone. Net insider buying over the past 90 days sits at over 736,000 shares for a combined value of approximately $1.5 million. For a micro-cap trading at $1.19, that kind of open-market buying is hard to dismiss — these are the people who see the clinical and operational pipeline closest.
The short side tells a story of rapid retreat. Short interest as a percentage of the free float climbed sharply through late March and into early April, peaking when shares outstanding on loan were running well above current levels. Since then, SI has fallen roughly 64% over the past month, landing near 8.9% of the float — still meaningful for a stock this small, but moving decisively in the wrong direction for bears. Borrow conditions reinforce that picture: the cost to borrow has dropped sharply from peaks near 180% APR in April to around 75% now, a 37% easing just in the past week. Availability is relatively generous at roughly 347% of short interest, meaning there is no shortage of shares to lend. The borrow market is loosening, not tightening.
The ORTEX short score of 58 is moderate — elevated enough to suggest lingering skepticism, but well off the more extreme readings seen earlier this spring when shorts were piling in. That earlier surge coincided with the stock sliding off higher levels; the subsequent covering rally has left the stock still down 6% on the week and 4% on the session heading into the print. Earnings history has been volatile. The most recent event in late March produced a single-day gain of 6.6%, while the event before that saw the stock fall nearly 19% in a day. Five-day windows have been equally extreme in both directions.
For a pre-revenue clinical-stage company — net loss is estimated near $9.5 million against minimal revenue — this earnings event is less about traditional financial metrics and more about pipeline progression, cash runway, and what management signals about the path forward from here.
See the live data behind this article on ORTEX.
Open DRMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
